Three SMEs and the University of Twente develop an extremely sensitive protein and virus detection platform
The SME companies Lead Pharma, LioniX and Surfix and the
University of Twente have jointly developed a biological
detection platform, BioMEANDER, that is up to a hundred
times more sensitive than existing techniques.
Amongst other applications, the partners plan to deploy the
platform to screen candidate drugs and to develop an
extremely selective virus detector.
The EFRO programme OP Oost awarded the partners
an R&D collaboration subsidy of €800,000 for the
BioMEANDER project, and the partners will also have
invested a total of €1.2 million in the project by the end of 2019.
Meet us at the 21st MicroTAS 2017
We will be present at the MicroTAS in Savannah,
Georgia from Monday, 23 October 2017 -
Thursday, 26 October 2017.
Surfix participates in one of the BIOCDx projects!
Surfix BV is proud to participate in the BIOCDx program
launched in January 2017. Within the project, partners from
four different countries - Greece, Germany, Switzerland and
The Netherlands - work on the development of a miniaturized,
ultra-sensitive and reliable Point-of-Care (PoC) device with a
disposable microfluidic cartridge for the monitoring of cancer biomarkers.
Micronit Microtechnologies en Surfix investeren in technologische verbetering medische thuistesten
Microtechnologiebedrijf Micronit en chemisch technologiebedrijf
Surfix slaan de handen ineen om medische testen voor thuisgebruik
te verbeteren. Zij ontvangen hiervoor een R&D samenwerkingssubsidie
uit het EFRO programma OP Oost.